ATE348629T1 - Behandlung von restenose und atherosklerose mit einem löslichen vegf rezeptor und angiopoietin-1 - Google Patents

Behandlung von restenose und atherosklerose mit einem löslichen vegf rezeptor und angiopoietin-1

Info

Publication number
ATE348629T1
ATE348629T1 AT00903106T AT00903106T ATE348629T1 AT E348629 T1 ATE348629 T1 AT E348629T1 AT 00903106 T AT00903106 T AT 00903106T AT 00903106 T AT00903106 T AT 00903106T AT E348629 T1 ATE348629 T1 AT E348629T1
Authority
AT
Austria
Prior art keywords
restenosis
atherosclerosis
angiopoietin
vegf receptor
treatment
Prior art date
Application number
AT00903106T
Other languages
English (en)
Inventor
Stephen E Epstein
Ran Kornowski
Shmuel Fuchs
Martin Leon
Original Assignee
Medstar Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medstar Res Inst filed Critical Medstar Res Inst
Application granted granted Critical
Publication of ATE348629T1 publication Critical patent/ATE348629T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
AT00903106T 1999-01-15 2000-01-05 Behandlung von restenose und atherosklerose mit einem löslichen vegf rezeptor und angiopoietin-1 ATE348629T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11597799P 1999-01-15 1999-01-15

Publications (1)

Publication Number Publication Date
ATE348629T1 true ATE348629T1 (de) 2007-01-15

Family

ID=22364512

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00903106T ATE348629T1 (de) 1999-01-15 2000-01-05 Behandlung von restenose und atherosklerose mit einem löslichen vegf rezeptor und angiopoietin-1

Country Status (9)

Country Link
US (2) US20030191055A1 (de)
EP (1) EP1146891B1 (de)
JP (1) JP2002534475A (de)
AT (1) ATE348629T1 (de)
AU (2) AU773050B2 (de)
CA (1) CA2359461A1 (de)
DE (1) DE60032459D1 (de)
HK (1) HK1041447A1 (de)
WO (1) WO2000041712A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057722A1 (en) * 1999-03-30 2006-03-16 Myocardial Therapeutics, Inc. Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
WO2002022176A1 (en) 2000-09-15 2002-03-21 Genvec, Inc. Method of modulating neovascularization
EP1515707A4 (de) * 2001-06-20 2005-10-19 Imclone Systems Inc Verfahren zur behandlung von atherosklerose und anderer entzündlicher erkrankungen
AU2003213687A1 (en) * 2002-03-04 2003-09-22 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
EP1615996A4 (de) * 2003-03-27 2006-11-15 Texase A & M University System Verwendungen von gefässendothel-wachstumsfaktor und kollageninduzierbarem protein typ i (vcip)
US20060154884A1 (en) * 2003-06-18 2006-07-13 Arnd Buchwald Use of a vegf receptor gener or gene product
US20090221673A1 (en) * 2005-09-13 2009-09-03 Rigby William F C Compositions and Methods for Regulating RNA Translation via CD154 CA-Dinucleotide Repeat
WO2008152507A2 (en) * 2007-03-16 2008-12-18 Multigene Vascular Systems, Inc. Compositions and methods for treating ophthalmic disorders
WO2023028004A1 (en) * 2021-08-23 2023-03-02 Avirmax, Inc. Compositions and methods for transgene expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434115T2 (de) * 1993-03-25 2005-10-27 Merck & Co., Inc. Inhibitor des wachstumsfaktors für gefässendothelzellen
CA2188575A1 (en) * 1995-02-28 1996-09-06 H. Kirk Hammond Gene transfer-mediated angiogenesis therapy
US6183752B1 (en) * 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
CA2375617A1 (en) * 1999-06-07 2000-12-14 Edwards Lifesciences Corporation Targeted angiogenesis

Also Published As

Publication number Publication date
EP1146891B1 (de) 2006-12-20
JP2002534475A (ja) 2002-10-15
EP1146891A1 (de) 2001-10-24
HK1041447A1 (zh) 2002-07-12
WO2000041712A1 (en) 2000-07-20
CA2359461A1 (en) 2000-07-20
AU2490200A (en) 2000-08-01
DE60032459D1 (de) 2007-02-01
US20060094657A1 (en) 2006-05-04
AU2004203652A1 (en) 2004-09-02
EP1146891A4 (de) 2002-07-17
US20030191055A1 (en) 2003-10-09
AU773050B2 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
TW200626526A (en) Pharmaceutical compositions for the treatment of neoplasms
IL146082A0 (en) Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
WO1999015167A3 (en) Use of citrus limonoids and flavonoids as well as tocotrienols for the treatment of cancer
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
AP2004003124A0 (en) Thiazole and oxazole derivatives which modulate PPAR activity
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
IL148920A0 (en) 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
DE60032459D1 (de) Behandlung von restenose und atherosklerose mit einem löslichen vegf rezeptor und angiopoietin-1
TR199901104T2 (xx) Farmas�tik bile�ikler.
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
ZA200003236B (en) Combination therapy for the treatment of migraine.
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
SG92610A1 (en) The use of des-aspartate-angiotensin i as an agent for the treatment and prevention of neointima formation, restenosis, and arteriosclerosis
ZA200309642B (en) Benzo (G) quinoline derivatives for treating glaucoma and myopia.
PT1206256E (pt) Terapia de combinacao utilizando pentafluorobenzenosulfonamida e compostos de platina
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
ZA200003235B (en) Combination therapy for the treatment of migraine.
ZA200002338B (en) Combination therapy for the treatment of migraine.
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
DE60025705D1 (de) Antikonvulsive derivate zur behandlung von essentiellem tremor
DE10080190D2 (de) Mittel zur Prävention und/oder Behandlung einer Gewebeveränderung mesenchymalen Ursprungs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties